Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Autolus Ltd.

www.autolus.com

Latest From Autolus Ltd.

New UK Biotech MiroBio Raises $34m For Autoimmune Disease Research

Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.

StartUps and SMEs Research & Development

Autolus Faces Life After Woodford With New Czech Backer

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

United Kingdom Financing

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Autolus Ltd.
  • Senior Management
  • Christian Itin, PhD, CEO
    Andrew J Oakley, SVP, CFO
    Martin Pule, SVP, CSO
    Vijay Reddy, MD, SVP, CMO
    Christopher Vann, SVP, COO
    Matthias Alder, SVP, CBO
  • Contact Info
  • Autolus Ltd.
    Phone: 20 3829 6230
    Forest House, 58 Wood Ln.
    White City
    London, W12 7RZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register